信迪利单抗联合化疗、经支气管镜介入治疗在晚期肺癌患者中的应用效果  

Application effect of sintilimab combined with chemotherapy and bronchoscopic interventional therapy in patients with advanced lung cancer

作　　者：黄小冰 黄惠娟 方志明 钱树苑 HUANG Xiaobing;HUANG Huijuan;FANG Zhiming;QIAN Shuyuan(Department of Respiratory Medicine,Zhangzhou Zhengxing Hospital,Zhangzhou 363000,Fujian,China;Department of Imaging,Zhangzhou Municipal Hospital of Fujian Province,Zhangzhou 363000,Fujian,China)

机构地区：[1]漳州正兴医院呼吸内科,福建漳州363000 [2]福建省漳州市医院影像科,福建漳州363000

出　　处：《癌症进展》2025年第7期774-778,782,共6页Oncology Progress

基　　金：福建省自然科学基金(2020J011277)。

摘　　要：目的探讨信迪利单抗联合化疗、经支气管镜介入治疗在晚期肺癌患者中的应用效果。方法根据治疗方法的不同将62例晚期肺癌患者分为对照组(n=37,化疗联合经支气管镜介入治疗)和观察组(n=25,信迪利单抗联合化疗、经支气管镜介入治疗)。比较两组患者的临床疗效、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+))水平、生活质量[卡氏功能状态(KPS)评分]、气促分级、肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC]、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平。结果观察组患者的疾病控制率(DCR)为76.00%,高于对照组患者的48.65%,差异有统计学意义(P﹤0.05)。治疗后,观察组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前及对照组,CD8^(+)水平低于本组治疗前和对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者KPS评分、FEV1水平、FVC水平及FEV1/FVC均高于本组治疗前,气促分级均低于本组治疗前,观察组患者KPS评分、FEV1水平、FVC水平及FEV1/FVC均高于对照组,气促分级低于对照组,差异均有统计学意义(P﹤0.05)。结论信迪利单抗联合化疗、经支气管镜介入治疗可提高晚期肺癌患者的临床疗效和生活质量,改善免疫微环境和肺功能,促进疾病恢复,降低肿瘤标志物水平。Objective To explore the application effect of sintilimab combined with chemotherapy and bronchoscopic interventional therapy in patients with advanced lung cancer.Method According to different treatment methods,62 patients with advanced lung cancer were divided into control group(n=37,chemotherapy combined with bronchoscopic interventional therapy)and observation group(n=25,sintilimab combined with chemotherapy and bronchoscopic interventional therapy).The clinical efficacy,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))levels,quality of life[Karnofsky performance status(KPS)score],grade of short breath,pulmonary function indicators[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC]and tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]levels were compared between the two groups.Result The disease control rate(DCR)of observation group was 76.00%,which was higher than 48.65%of control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in observation group were higher than those before treatment and control group,and the level of CD8^(+)was lower than those before treatment and control group,and the differences were statistically significant(P<0.05).After treatment,the KPS scores,FEV1 levels,FVC levels and FEV1/FVC in both groups were higher than those before treatment,and the grades of short breath were lower than those before treatment,the KPS score,FEV1 level,FVC level and FEV1/FVC in observation group were higher than those in control group,and the grade of short breath was lower than that in control group,and the differences were statistically significant(P<0.05).Conclusion Sintilimab combined with chemotherapy and bronchoscopic interventional therapy can improve the clinical efficacy and quality of life in patients with advanced lung cancer,improve the immune microenvironment and lung function,promote disease reco

关 键 词：信迪利单抗 化疗 经支气管镜介入治疗 晚期肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]